Chang, Hanman

Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer

Liu, X., Bao, X., Hu, M., Chang, H., Jiao, M., Cheng, J., Xie, L., Huang, Q., Li, F., & Li, C.-Y. (2020) · Nature

Cancer Immunotherapy and BiomarkersImmunotherapy and Immune Responses

Cited by 490

Targeting proprotein convertase subtilisin/kexin type 9 (PCSK9): From bench to bedside

Bao, X., Liang, Y., Chang, H., Cai, T., Feng, B., Gordon, K., Zhu, Y., Shi, H., He, Y., & Xie, L. (2024) · Signal Transduction and Targeted Therapy

Lipoproteins and Cardiovascular HealthCholesterol and Lipid Metabolism

Cited by 187